Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes

Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes Aim: The aim of this study was to examine the efficacy and safety of topiramate as an adjunct to diet and exercise in drug‐naive, obese subjects with type 2 diabetes. Methods: Drug‐naive individuals with type 2 diabetes, body mass index (BMI) of ≥27 and <50 kg/m2 and haemoglobin A1c (HbA1c) of <10.5% were enrolled into the study. All the individuals participated in a non‐pharmacologic weight loss program (Pathways to Change®; Johnson & Johnson Healthcare Systems, Piscataway, NJ, USA) throughout the trial. After a 6‐week placebo run‐in, the subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Subjects were scheduled for 8‐week titration and 52‐week maintenance phases. The study was ended early; efficacy data were reported for a predefined modified intent‐to‐treat (MITT) population (n = 229), with 40 weeks of treatment. All the subjects who provided any safety data were included in the safety population (n = 535). Results: Baseline mean weight was 103.7 kg, BMI 36 kg/m2 and HbA1c 6.7% across all treatment groups. By the end of week 40, the placebo, the topiramate 96 mg/day and topiramate 192 mg/day groups lost 2.5, 6.6 and 9.1% of their baseline body weight respectively (p < 0.001 vs. placebo, MITT population using last observation carried forward). The decrease in HbA1c was 0.2, 0.6 and 0.7% respectively (p < 0.001 vs. placebo, MITT). Topiramate significantly reduced blood pressure and urinary albumin excretion; a weight‐loss‐independent HbA1c improving effect of topiramate was demonstrated. Adverse events were predominantly related to central nervous system (CNS). Conclusions: Topiramate as an add‐on treatment to lifestyle improvements produced significant weight loss and improved glucose homeostasis in obese, drug‐naive subjects with type 2 diabetes. These treatment advantages should be balanced against the occurrence of adverse events in the CNS. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Obesity & Metabolism Wiley

Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes

Loading next page...
 
/lp/wiley/topiramate-in-the-treatment-of-obese-subjects-with-drug-naive-type-2-z0AeK6Kxhh
Publisher
Wiley
Copyright
2006 Blackwell Publishing Ltd
ISSN
1462-8902
eISSN
1463-1326
DOI
10.1111/j.1463-1326.2006.00618.x
Publisher site
See Article on Publisher Site

Abstract

Aim: The aim of this study was to examine the efficacy and safety of topiramate as an adjunct to diet and exercise in drug‐naive, obese subjects with type 2 diabetes. Methods: Drug‐naive individuals with type 2 diabetes, body mass index (BMI) of ≥27 and <50 kg/m2 and haemoglobin A1c (HbA1c) of <10.5% were enrolled into the study. All the individuals participated in a non‐pharmacologic weight loss program (Pathways to Change®; Johnson & Johnson Healthcare Systems, Piscataway, NJ, USA) throughout the trial. After a 6‐week placebo run‐in, the subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Subjects were scheduled for 8‐week titration and 52‐week maintenance phases. The study was ended early; efficacy data were reported for a predefined modified intent‐to‐treat (MITT) population (n = 229), with 40 weeks of treatment. All the subjects who provided any safety data were included in the safety population (n = 535). Results: Baseline mean weight was 103.7 kg, BMI 36 kg/m2 and HbA1c 6.7% across all treatment groups. By the end of week 40, the placebo, the topiramate 96 mg/day and topiramate 192 mg/day groups lost 2.5, 6.6 and 9.1% of their baseline body weight respectively (p < 0.001 vs. placebo, MITT population using last observation carried forward). The decrease in HbA1c was 0.2, 0.6 and 0.7% respectively (p < 0.001 vs. placebo, MITT). Topiramate significantly reduced blood pressure and urinary albumin excretion; a weight‐loss‐independent HbA1c improving effect of topiramate was demonstrated. Adverse events were predominantly related to central nervous system (CNS). Conclusions: Topiramate as an add‐on treatment to lifestyle improvements produced significant weight loss and improved glucose homeostasis in obese, drug‐naive subjects with type 2 diabetes. These treatment advantages should be balanced against the occurrence of adverse events in the CNS.

Journal

Diabetes Obesity & MetabolismWiley

Published: May 1, 2007

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off